Oncol Res Treat. 2017;40(1-2):46-48. doi: 10.1159/000455146. Epub 2017 Jan 18.
Plasmablastic lymphoma (PBL) is an uncommon variant of diffuse large B-cell lymphoma that is characterized by its plasmacytoid features, aggressive tendencies, and frequent association with human immunodeficiency virus (HIV) infection or other immunocompromised states. Multi-agent, intensive chemotherapy regimens are recommended as first-line treatment by the National Comprehensive Cancer Network. However, the toxicity of these regimens is high and prognosis remains poor.
We report a patient with HIV-negative PBL who achieved complete response and durable remission using a lenalidomide-based chemotherapy regimen as first-line therapy.
Cyclophosphamide, lenalidomide, dexamethasone (CRD) may provide an alternative initial therapeutic option for patients with PBL who cannot tolerate the intensive chemotherapy regimens currently recommended.
浆母细胞淋巴瘤（PBL）是弥漫性大 B 细胞淋巴瘤的一种罕见变异型，其特征为浆细胞样特征、侵袭性倾向以及频繁与人类免疫缺陷病毒（HIV）感染或其他免疫功能低下状态相关。国家综合癌症网络推荐多药物、强化化疗方案作为一线治疗。然而，这些方案的毒性很高，预后仍然很差。
我们报告了一例 HIV 阴性 PBL 患者，该患者使用来那度胺为基础的化疗方案作为一线治疗，达到完全缓解和持久缓解。
环磷酰胺、来那度胺、地塞米松（CRD）可能为不能耐受目前推荐的强化化疗方案的 PBL 患者提供另一种初始治疗选择。
